Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estimulación de Alta Frecuencia para Mejorar la Cognición, la Movilidad y el Afecto en Personas con Deterioro Cognitivo Subjetivo

22 de septiembre de 2026 actualizado por: University of Florida

Estimulación de alta frecuencia para mejorar la cognición, la movilidad y el afecto en personas con deterioro cognitivo subjetivo

The goal is to determine whether three months of at least three times / week of sensory flicker stimulation improves cognition, mobility, and affect in healthy older adults and older adults with and without Subjective Cognitive Decline (SCD). Investigators will also determine whether the intervention slows cortical thinning and declines in brain functional network segregation and changes in blood biomarkers of Alzheimer's Disease (AD).

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Alyssa Hayes
  • Número de teléfono: (352) 273-2134
  • Correo electrónico: alyssa.hayes@ufl.edu

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Florida
      • Gainesville, Florida, Estados Unidos, 32611
        • Reclutamiento
        • University of Florida
        • Contacto:
        • Contacto:
        • Sub-Investigador:
          • Natalie C. Ebner, PhD
        • Investigador principal:
          • Rachael Seidler, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

65 años a 89 años (Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

  • Community dwelling men and women 65-89 years old
  • Ability to walk unassisted for 10 min
  • English speaking Additional Inclusion Criteria for SCD
  • No evidence of dementia or MCI based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) score within normal limits for age, education, and sex using the NACC Uniform Data Set (UDS) norms
  • Global Clinic Dementia Rating (CDR) score must be 0 or 0.531
  • Subjective report of cognitive complaints with scores >20 on the Cognitive Change Index (CCI-20), a validated scale of subjective cognitive decline6; this scale consists of 20 items that are rated on a 5-point Likert scale, where 1= "Normal: No change compared to 5 years ago", 3= "Mild Problem: Some change compared to 5 years ago) and 5="Severe Problem: Much worse compared to 5 years ago"
  • Family history of dementia/probable AD in first degree relative (parents, children, siblings)
  • Normal functional behavior in terms of daily activities, based on the Functional Activities Scale In line with recommendations of the SCD task force an informant must be available for two reasons: a) to provide information about the participant's cognition using the informant version of the CDR and CCI-20, and b) to corroborate normal IADL's on the Functional Activity Questionnaire (informant data will be collected via a phone call and linked by code with the participant data).

Exclusion criteria

  • If participants score less than 21 on the Telephone Interview for Cognitive Status (TICS)
  • Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.)
  • Severe visual impairment or corrected visual acuity less than 20/40 (as per self-report), which would preclude completion of assessments
  • Inability to undergo MRI brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, certain non-removable body jewelry, or shrapnel containing ferromagnetic metal
  • History of severe stroke
  • Epilepsy or family history of epilepsy, past seizure history, as well as history of migraines
  • Current use of psychotropic medications
  • Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer)
  • Report of lower extremity pain due to osteoarthritis that significantly limits mobility
  • Diagnosis or treatment for rheumatoid arthritis
  • Known neuromuscular disorder or overt neurological disease (e.g., Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)
  • Unable to communicate because of severe hearing loss or speech disorder
  • Planned surgical procedure or hospitalization in the next 4 months (joint replacement, coronary artery bypass graft, etc.)
  • Severe pulmonary disease, requiring the use of supplemental oxygen
  • Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
  • Use of walker or wheelchair

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador falso: Control

Participants in this group will receive the control stimulation at the slower rate.

This group will wear visual occlusion glasses with visible stimulation at 1 Hz

Experimental: Experimental

Participants in this group will receive the experimental stimulation at the faster rate.

This group will wear visual occlusion glasses with visible stimulation at 16.67 Hz (corresponding to flicker of 32-36 Hz)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cognition - The Tablet-based Cognitive Assessment Tool (TabCAT)
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This test battery assesses performance in various cognitive components. A composite score across subtasks will be computed. Higher scores in the composite indicates better cognition.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Mobility - Grip Strength
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This test assesses grip strength in kg. A composite score across trials will be computed. Higher scores indicate more strength.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Mobility - 10 Meter Gait Speed
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This test assesses speed in seconds during unassisted walking for 10 meters. A composite score across trials will be computed. Higher scores indicate lower walking speed.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Mobility - Clinical Test of Sensory Interaction on Balance (CTSIB)
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This test assesses sway area (measured in m^2/s^4) with eyes open and closed while standing on a hard and a foam surface. A larger sway area indicates greater postural instability and poorer balance control during specific sensory conditions

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Affect - Profile of Mood States Second Edition (POMS-2)
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This questionnaire assesses transient feelings and mood on a scale from 0 = not at all to 4 = extremely). A composite score across items will be computed as primary outcome. Higher scores indicate greater intensity of the mood state.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Affect - Ryff Scales of Psychological Wellbeing
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This questionnaire assesses psychological well-being via 42 statements using a 6-point scale (1 = strongly agree; 6 = strongly disagree). A composite score across items will be computed as primary outcome. Higher scores indicate greater psychological wellbeing.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Affect - Satisfaction with Life Scale
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

This questionnaire assesses satisfaction with life. A composite score across items will be computed as primary outcome. The possible range of scores is 5-35. Scores between 5-9 indicate the respondent is extremely dissatisfied with life, whereas scores between 31-35 indicate the respondent is extremely satisfied. A composite score across items will be computed as primary outcome. Higher scores indicate greater life satisfaction.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Brain Markers - Structure
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

Cortical thickness (in mm) will be determined via a T1 MRI scan in dorsolateral prefrontal, sensorimotor, and insular cortices using the CAT computational anatomy toolbox. Greater values indicate greater cortical thickness.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
AD Biomarkers - Amyloid
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

These assays will determine amyloid (e.g., Aβ17) sensitive to Alzheimer's Disease. Higher values indicate higher amyloid levels.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Biomarkers - P-Tau
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

These assays will determine p-tau levels sensitive to Alzheimer's Disease. A composite score across items will be computed as primary outcome. Higher values indicate higher p-tau levels.

Baseline, halfway through (1.5 months), and post-intervention (3 months)
Brain Markers - Network Function
Periodo de tiempo: Baseline, halfway through (1.5 months), and post-intervention (3 months)

Brain network function will be assessed via resting-state fMRI (in Blood oxygen level dependent response) to capture functional segregation of dorsolateral prefrontal, sensorimotor, and insular networks using the CONN toolbox. Greater values indicate greater functional connectivity.

Baseline, halfway through (1.5 months), and post-intervention (3 months)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Rachael C. Seidler, University of Florida
  • Investigador principal: Natalie C. Ebner, PhD, University of Florida

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de agosto de 2026

Finalización primaria (Estimado)

31 de octubre de 2028

Finalización del estudio (Estimado)

31 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

10 de septiembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

5 de febrero de 2026

Publicado por primera vez (Actual)

9 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB202500587

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Upon study completion, published data will be made available via established repositories (e.g., NIH OpenNeuro, OSF).

Marco de tiempo para compartir IPD

Upon publication acceptance of data.

Criterios de acceso compartido de IPD

Via open source repositories

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir